IN2015DN04172A - - Google Patents

Info

Publication number
IN2015DN04172A
IN2015DN04172A IN4172DEN2015A IN2015DN04172A IN 2015DN04172 A IN2015DN04172 A IN 2015DN04172A IN 4172DEN2015 A IN4172DEN2015 A IN 4172DEN2015A IN 2015DN04172 A IN2015DN04172 A IN 2015DN04172A
Authority
IN
India
Prior art keywords
lateral sclerosis
amyotrophic lateral
individual
therapeutic agent
ghs
Prior art date
Application number
Other languages
English (en)
Inventor
Tsuyoshi Matsuo
Norihito Murayama
Mayumi Furuya
Original Assignee
Daiichi Sankyo Companyltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Companyltd filed Critical Daiichi Sankyo Companyltd
Publication of IN2015DN04172A publication Critical patent/IN2015DN04172A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/25Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Cell Biology (AREA)
IN4172DEN2015 2012-10-24 2013-10-23 IN2015DN04172A (enExample)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2012234300 2012-10-24
PCT/JP2013/078743 WO2014065341A1 (ja) 2012-10-24 2013-10-23 筋萎縮性側索硬化症治療剤

Publications (1)

Publication Number Publication Date
IN2015DN04172A true IN2015DN04172A (enExample) 2015-10-16

Family

ID=50544716

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4172DEN2015 IN2015DN04172A (enExample) 2012-10-24 2013-10-23

Country Status (11)

Country Link
US (1) US20150265680A1 (enExample)
EP (1) EP2913063B1 (enExample)
JP (1) JP6262661B2 (enExample)
KR (3) KR20150070180A (enExample)
CN (2) CN110354265A (enExample)
AU (1) AU2013335678B9 (enExample)
BR (1) BR112015009107A2 (enExample)
CA (1) CA2889499C (enExample)
IN (1) IN2015DN04172A (enExample)
RU (1) RU2655811C2 (enExample)
WO (1) WO2014065341A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016077498A1 (en) 2014-11-12 2016-05-19 Lyric Pharmaceuticals Inc. Treatment of enteral feeding intolerance
WO2017083882A1 (en) * 2015-11-11 2017-05-18 Lyric Pharmaceuticals Inc. Treatment of enteral feeding intolerance and other conditions using ulimorelin analogs
KR20210102294A (ko) * 2018-12-06 2021-08-19 바이오젠 엠에이 인코포레이티드 근위축성 측삭 경화증에서 치료요법적 중재를 안내하기 위한 신경필라멘트 단백질
EP4611737A1 (en) * 2022-11-03 2025-09-10 Lumos Pharma, Inc. Compactable oral formulations of ibutamoren

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668254A (en) 1990-05-11 1997-09-16 Romano Deghenghi D-2-alkyl-tryptophan and peptides containing same
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
US5578593A (en) 1992-12-11 1996-11-26 Merck & Co., Inc. Spiro piperidines and homologs promote release of growth hormone
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6576656B1 (en) 1998-08-20 2003-06-10 Sumitomo Pharmaceuticals Co., Ltd. Oxindole derivative
PT1795598E (pt) * 1999-07-23 2010-01-05 Kenji Kangawa Novos péptidos
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
EP1258250B1 (en) * 1999-12-28 2005-09-14 Kaken Pharmaceutical Co., Ltd. Nerve protective drugs
CA2407659C (en) 2000-06-13 2010-11-09 Zentaris Ag Growth hormone secretagogues
BRPI0306644B8 (pt) 2002-04-11 2021-05-25 Asubio Pharma Co Ltd método para produzir um peptídeo modificado
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
JP2005239712A (ja) 2004-01-30 2005-09-08 Kaken Pharmaceut Co Ltd 神経突起伸展剤
WO2006079077A2 (en) * 2005-01-20 2006-07-27 Acadia Pharmaceuticals Inc. Use of diltiazem or analogs thereof as modulators of ghrelin receptor
US7829589B2 (en) 2005-06-10 2010-11-09 Elixir Pharmaceuticals, Inc. Sulfonamide compounds and uses thereof
WO2007046347A1 (ja) * 2005-10-18 2007-04-26 Ono Pharmaceutical Co., Ltd. 筋萎縮性側索硬化症患者の運動神経保護用医薬
ES2596885T3 (es) 2006-06-07 2017-01-12 Genzyme Corporation Terapia génica para esclerosis lateral amiotrófica y otros trastornos de la medula espinal
JP2008127377A (ja) 2006-11-24 2008-06-05 Jichi Medical Univ Ghs−r作動薬を含有してなるメタボリックシンドローム又は高血圧症の予防・治療剤。
KR100946084B1 (ko) 2008-03-27 2010-03-10 주식회사 하이닉스반도체 반도체 소자의 수직형 트랜지스터 및 그 형성방법
MX2010010495A (es) * 2008-04-03 2010-10-15 Hoffmann La Roche Uso de variantes del factor de crecimiento similar a la insulina (igf-i) pegiladas para el tratamiento de trastornos neuromusculares.

Also Published As

Publication number Publication date
EP2913063B1 (en) 2019-09-11
JPWO2014065341A1 (ja) 2016-09-08
AU2013335678B9 (en) 2024-12-12
CN110354265A (zh) 2019-10-22
KR20200108494A (ko) 2020-09-18
BR112015009107A2 (pt) 2017-11-14
WO2014065341A1 (ja) 2014-05-01
KR102499918B1 (ko) 2023-02-14
JP6262661B2 (ja) 2018-01-17
AU2013335678B2 (en) 2017-10-26
CA2889499A1 (en) 2014-05-01
CA2889499C (en) 2019-09-10
CN104853778A (zh) 2015-08-19
HK1214152A1 (en) 2016-07-22
EP2913063A1 (en) 2015-09-02
KR20220051418A (ko) 2022-04-26
RU2015119472A (ru) 2016-12-20
KR20150070180A (ko) 2015-06-24
US20150265680A1 (en) 2015-09-24
EP2913063A4 (en) 2016-07-20
RU2655811C2 (ru) 2018-05-29
AU2013335678A1 (en) 2015-05-21

Similar Documents

Publication Publication Date Title
Panlilio et al. Inhibition of FAAH and activation of PPAR: new approaches to the treatment of cognitive dysfunction and drug addiction
ZA202108745B (en) Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
IN2015KN00414A (enExample)
PH12014502516B1 (en) Formulations and methods for vaginal delivery of antiprogestins
MY162895A (en) A combination of an opioid agonist and an opioid antagonist in the treatment of parkinson's disease
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
PH12014500472A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
EA027953B9 (ru) АЗОТСОДЕРЖАЩИЕ 5-ЧЛЕННЫЕ ГЕТЕРОЦИКЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ЯДЕРНОГО ОРФАНОВОГО РЕЦЕПТОРА RORγ
PH12012501480A1 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX341482B (es) Antagonistas del receptor ep4 y su uso en el tratamiento de enfermedades mediadas por la il-23.
MX2014001088A (es) Ciertos inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas, y metodos de uso de las mismas.
WO2011157416A3 (de) Transdermale verabreichung von memantin
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
IN2015DN04172A (enExample)
HK1223825A1 (zh) 包含阿曲生坦的稳定化药物剂型
HK1203394A1 (en) Ghrelin receptor agonists for the treatment of achlorhydria
MX2016006657A (es) Antagonistas de gastrina (por ejemplo, yf476, netazepido) para el tratamiento y prevencion de osteoporosis.
SG10201809506TA (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MX2014014817A (es) Compuestos para el tratamiento de inflamacion y dolor.
AU2018279669A8 (en) Carboxylic acid derivative as at AT2R receptor antagonist
MY198069A (en) Method for preventing or treating autism spectrum disorders by benzoic acid salt
MX337593B (es) Gemcabeno y derivados para tratar la pancreatitis.
MX2014014813A (es) Uso de agonistas o antagonistas inversos para el receptor de grelina para tratar trastornos del sueño.
PH12019502122A1 (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
EA201300722A1 (ru) Применение агониста каппа-опиоидных рецепторов периферического действия ici 204,448 для приготовления средств для лечения никотиновой зависимости